EP0531382A1 - Composes de 1,2,4-triazolones a substitution n utilises dans le traitement de troubles cardiovasculaires - Google Patents

Composes de 1,2,4-triazolones a substitution n utilises dans le traitement de troubles cardiovasculaires

Info

Publication number
EP0531382A1
EP0531382A1 EP91910101A EP91910101A EP0531382A1 EP 0531382 A1 EP0531382 A1 EP 0531382A1 EP 91910101 A EP91910101 A EP 91910101A EP 91910101 A EP91910101 A EP 91910101A EP 0531382 A1 EP0531382 A1 EP 0531382A1
Authority
EP
European Patent Office
Prior art keywords
phenyl
aralkyl
alkyl
butyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91910101A
Other languages
German (de)
English (en)
Inventor
Robert E. Manning
David B. Reitz
Horng-Chih Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of EP0531382A1 publication Critical patent/EP0531382A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Abstract

L'invention concerne une classe de composés de 1,2,4-triazolones à substitution N utilisés dans le traitement de troubles cardiovasculaires. Les composés présentant un intérêt particulier sont des antagonistes d'angiotensine II de la formule (I), dans laquelle R1 est choisi parmi 2-oxo-2-(tricyclo[3.3.1.1.3.7]dec-2-yl)ethyl, 3-phénylpropyle, 2-oxo-2-phényléthyle, 2-hydroxy-2-phényléthyle, 1,1-diméthyléthyloxycarbonylméthyle, hexyle, éthoxycarbonylméthyle, carboxyméthyle, 1-naphtalènylméthyle, 2-cyclohexyléthyle, pentyl, éthoxycarbonyleméthoxyéthyle remplacés par phényle, carboxyméthoxyéthyle remplacés par phényle, 3,5,5-triméthylhexyle, (2-phénylméthoxy)-1-(phénylméthyle)-E-éthènyle, 1-benzoyl-2-phényléthyle, 1-oxobutyl, 2-(2,5-diméthyoxyphényle)-2-oxoéthyle, 2-phényle-2-(phénylméthoxy)éthyle, 2-(2,5-diméthyoxy-phényle)-2-hydroxyéthyle, 2-naphtalènylméthyle, méthoxycarbonyle-butyl, éthoxycarbonyléthyle remplacés par benzoyle, 1-benzyoyle-1-méthyléthyle, acide-1-pentanoïque, cyclopropylméthyle, 3-phényle-2E-propényle et 3-acétonitryle; dans laquelle R2 est choisi entre éthyle, n-propyle, isopropyle, n-butyle, sec-butyle, isobutyle, 4-méthylbutyle, tert-butyle, n-pentyle, néopentyle, 1-cyanobutyle, propylthio et butylthio; dans laquelle R3 à R11 représentent chacun hydrido à condition qu'au moins un des éléments R5 et R9 soient choisis parmi COOH, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH, (a), (b) et (c), dans lesquels R42 et R43 sont choisis indépendamment entre chloro, cyano, nitro, trifluorométhyle, méthoxycarbonyle et trifluorométhylsulfonyle. Ces composés sont particulièrement utiles dans le traitement ou la régulation de l'hypertension et de l'insuffisance cardiaque.
EP91910101A 1990-05-25 1991-05-23 Composes de 1,2,4-triazolones a substitution n utilises dans le traitement de troubles cardiovasculaires Withdrawn EP0531382A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US529079 1983-09-02
US52907990A 1990-05-25 1990-05-25

Publications (1)

Publication Number Publication Date
EP0531382A1 true EP0531382A1 (fr) 1993-03-17

Family

ID=24108443

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91910101A Withdrawn EP0531382A1 (fr) 1990-05-25 1991-05-23 Composes de 1,2,4-triazolones a substitution n utilises dans le traitement de troubles cardiovasculaires

Country Status (5)

Country Link
EP (1) EP0531382A1 (fr)
JP (1) JPH05506443A (fr)
AU (1) AU7903091A (fr)
CA (1) CA2083735A1 (fr)
WO (1) WO1991018888A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074412C (zh) * 1996-09-18 2001-11-07 立德化学株式会社 新的2,4－二氧代吡咯烷和2,4－二氧代四氢呋喃衍生物以及含有它们作为活性成分的药物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411980A (en) * 1989-07-28 1995-05-02 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
US5164403A (en) * 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
CA2109524A1 (fr) * 1991-05-10 1992-11-11 Prasun K. Chakravarty Derives acides d'aralkyltriazole, antagonistes de l'angiotensine ii
GB9716446D0 (en) * 1997-08-05 1997-10-08 Agrevo Uk Ltd Fungicides
EP1044958A4 (fr) * 1997-11-14 2004-11-17 Sumitomo Chemical Co PROCEDE DE PRODUCTION DE tert-BUTYL 4'-METHYL-2-BIPHENYLCARBOXYLATE
WO1999031099A1 (fr) * 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951B1 (fr) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2970384A1 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
EP0412594B1 (fr) * 1989-07-28 1996-01-03 Merck & Co. Inc. Triazolinones, triazolinethiones et triazolinimines substituées comme antagonistes d'angiotensine II

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9118888A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074412C (zh) * 1996-09-18 2001-11-07 立德化学株式会社 新的2,4－二氧代吡咯烷和2,4－二氧代四氢呋喃衍生物以及含有它们作为活性成分的药物

Also Published As

Publication number Publication date
WO1991018888A1 (fr) 1991-12-12
CA2083735A1 (fr) 1991-11-26
AU7903091A (en) 1991-12-31
JPH05506443A (ja) 1993-09-22

Similar Documents

Publication Publication Date Title
US5087634A (en) N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US20010020100A1 (en) N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
US5098920A (en) 1h-substituted-1,2,4-triazole compounds and methods of use thereof for treatment of cardiovascular disorders
US5451593A (en) Method of using 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of a glaucoma disorder
EP0531382A1 (fr) Composes de 1,2,4-triazolones a substitution n utilises dans le traitement de troubles cardiovasculaires
US6451833B1 (en) N-substituted (α-imidazolyl-toluyl)pyrrole compounds for treatment of circulatory disorders
US5155117A (en) 1-arylheteroarylalkyl substituted-1h-1,2,4-triazole compounds for treatment of circulatory disorders
US6630497B2 (en) 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders
US5140036A (en) 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
US5451597A (en) Treatment of circulatory disorders using n-substituted (α-imidazolyl-toluyl) pyrrole angiotensin II antagonists
US6008368A (en) Pharmaceutical compositions for treatment of circulatory disorders using N-substituted (α-imidazolyl-toluyl) pyrrole aniotensin II antagonists
US5484937A (en) N-substituted N-(α-triazolyl-toluyl)pyrrole compounds for treatment of circulatory disorders
US5175180A (en) N-substituted n-(alpha-triazolyl-toluyl)pyrrole compounds and use for treatment of circulatory disorders
US5229406A (en) 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
US5238952A (en) N-substituted imidazol-2-one compounds for treatment of circulatory disorders
IE911801A1 (en) N-substituted-1,2,4-triazolone compounds for treatment of¹cardiovascular disorders
US7132437B2 (en) Renal-selective biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonists for treatment of hypertension

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921005

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19931223